Previous slide decks focused on landmark studies which used a monoclonal antibody approach to inhibit PCSK9. The next in this series discusses inclisiran, a small interfering RNA therapy, which prevents production of PCSK9 at its primary source in the liver.
Find out more »Keep up to date with latest news and analyses from PCSK9 inhibitor trials.
For expert analysis and insights
16th Virtual Closed Scientific Expert Meeting of the Editorial Board
Statin intolerance: Do we need a new clinical definition and management strategies?
Professor Ulrich Laufs provides a European perspective to this question.
Professor Paul Thompson gives a US perspective to what is needed for research into statin intolerance and statin-associated muscle symptoms.
Reducing residual risk: Are cholesterol crystals the next target?
Prof John Chapman Pitié-Salpetrière University Hospital, INSERM, Paris France discusses how cholesterol crystals play a crucial role in atherothrombosis, and potential therapeutic options.
Related reports: